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Bietti crystalline corneoretinal dystrophy (BCD) is an autosomal recessive retinal dystrophy characterized bymultiple
glistening intraretinal crystals scattered over the fundus, a characteristic degeneration of the retina, and sclerosis
of the choroidal vessels, ultimately resulting in progressive night blindness and constriction of the visual ﬁeld. The
BCD region of chromosome 4q35.1 was reﬁned to an interval ﬂanked centromerically by D4S2924 by linkage and
haplotype analysis; mutations were found in the novel CYP450 family member CYP4V2 in 23 of 25 unrelated
patients with BCD tested. The CYP4V2 gene, transcribed from 11 exons spanning 19 kb, is expressed widely.
Homology to other CYP450 proteins suggests that CYP4V2 may have a role in fatty acid and steroid metabolism,
consistent with biochemical studies of patients with BCD.
Introduction
Bietti crystalline corneoretinal dystrophy (BCD [MIM
210370]) is an autosomal recessive retinal dystrophy
ﬁrst described by Bietti (1937). The condition is char-
acterized by numerous tiny glistening yellow-white crys-
tals at the posterior pole of the retina associated with
atrophy of the retinal pigment epithelium (RPE), pig-
ment clumps, and choroidal sclerosis. Most cases have
similar crystals at the corneoscleral limbus (Kaiser-Kup-
fer et al. 1994). Clinically, BCD is progressive; most
patients develop decreased vision, nyctalopia, and para-
central scotomata between the 2nd and 4th decade of
life. Later, patients develop peripheral visual ﬁeld loss
and marked visual impairment, usually progressing to
legal blindness by the 5th or 6th decade of life (Kaiser-
Kupfer et al. 1994).
Although patients with BCD from Europe, North and
South America, the Middle East, and Africa have been
described, BCD has been reported to be more common
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in East Asia, especially in Chinese and Japanese pop-
ulations (Hu 1983). An epidemiological survey of ge-
netic disease in a general population in China estimated
the gene frequency to be 0.005 (Hu 1982). However,
BCD accounted for ∼3% (3 of 104 index patients) of
all nonsyndromic retinitis pigmentosa (RP) and 10% of
nonsyndromic autosomal recessive “RP” in a recent se-
ries from Europe (Mataftsi et al., in press).
Histopathology shows advanced panchorioretinal at-
rophy, with crystals and complex lipid inclusions seen
in choroidal ﬁbroblasts, corneal keratocytes, and con-
junctival and skin ﬁbroblasts, as well as in circulating
lymphocytes (Welch 1977; Wilson et al. 1989; Kaiser-
Kupfer et al. 1994). These ﬁndings suggest that BCD
may result from a systemic abnormality of lipid metab-
olism. Cells cultured from patients with BCD have ab-
normally high levels of triglycerides and cholesterol
storage (Lee et al. 2001). Conversely, metabolism of
labeled fatty acid precursors into n-3 polyunsaturated
fatty acids (n-3PUFA) is decreased (Lee et al. 2001).
Both ﬁndings suggest that a deﬁciency or dysfunction
of a lipid metabolic enzyme or fatty acid–binding pro-
tein could cause decreased uptake and transfer between
lipid pools. In addition, deﬁcient elongation and desat-
uration of fatty acid precursors could cause the deposit
of lipid within the diseased cells in crystalline form (Lee
et al. 2001). In this regard, lymphocytes from patients
with BCD lack two fatty acid–binding activities (Lee et
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al. 1998), but the relationship between the disease and
these two absent binding activities remains unclear. In
sum, these ﬁndings suggest that BCD may result from
a systemic abnormality of lipid metabolism.
Previously, the BCD locus was linked toD4S426 (max-
imum LOD score [Zmax]p 4.81; recombination fraction
[v]p 0), D4S2688 ( ; ), and D4S2299Z p 3.98 vp 0max
( ; ) on chromosome 4q35-4qtel (JiaoZ p 5.31 vp 0max
et al. 2000). Multipoint analysis conﬁrmed linkage to the
region telomeric of D4S1652, with a maximum multi-
point LOD score of 5.3 located 4 cM telomeric ofmarker
D4S2930. The present study utilizes haplotype and link-
age analysis to reﬁne the critical region for the BCD locus
to the region of chromosome 4q35 distal to D4S2924
and identiﬁes mutations in the CYP4V2 gene in 23 of
25 unrelated patients with BCD. CYP4V2 is a previously
uncharacterized gene that encodes a widely expressed
525–amino acid CYP450 family member, the structure
of which suggests its involvement in fatty acid metabo-




This project was approved by the National Eye In-
stitute institutional review board. The patients admitted
to the study gave their informed consent, and the study
adhered to the tenets of the Declaration of Helsinki.
Clinical diagnostic procedures, diagnostic criteria, and
exclusion criteria have been described elsewhere (Jiao et
al. 2000). Diagnosis was conﬁrmed by the presence of
lipid inclusions in lymphocytes in families 33001–33012
and 33015, as well as in one isolated European individ-
ual, 3300001. On the basis of the ethnic origin of the
families, 50 unrelated and unaffected individuals (12
Chinese, 16 Japanese, and 22 European) were enrolled
in this study as unaffected controls. DNA was extracted
either directly from blood or from transformed lym-
phoblastoid cell lines (Smith et al. 1989).
Genotyping and Linkage Analyses
Two-point linkage analyses were performed with the
FASTLINK implementation of the MLINK program in
the LINKAGE program package (Lathrop and Lalouel
1984; Cottingham et al. 1993). BCD was analyzed as a
fully penetrant autosomal recessive trait. The gene fre-
quency of BCD was set at 0.005 (Hu 1983). For linkage
and haplotype analysis, the markers in the BCD region
were arranged according to the physical map (ﬁg. 1; and
see below). Haplotypes were constructed with 14 mi-
crosatellite markers and the mutation locus found in
families with BCD to minimize recombinational events.
Physical Mapping
A YAC contig was constructed as a ﬁrst step, followed
by BAC and P1-derived artiﬁcial chromosome (PAC)
maps in the candidate region (ﬁg. 2). Total yeast genomic/
YAC DNA was isolated and analyzed (Ayyagari et al.
1996). PAC clones were screened from a human genomic
DNA PAC library, RPCI-1 (Incyte Genomics), by PCR
with eight microsatellite markers in the linkage study
(D4S3051, D4S2921, D4S426, D4S2688, D4S2299,
D4S2930, D4S1652, and D4S2283) and another 20 STS
markers located in the BCD region (D4S254, D4S187,
D4S862, D4S3214, D4S130, D4S2930, D4S2441,
D4S845, D4S592, D4S1369, D4S3186, D4S3212,
D4S3239, WI5353, WI140, T78431, SGC38233,
SHGC67241, D4S1621, and D4S139). Twenty BAC
clones (RP11-308K2, 264F11, 237D3, 565A3, 713C19,
174N10, 219G10, 16M7, 16L12, 765P10, 553E4,
354H17, 818C3, 45F23, 462G22, 215O6, 30B7, 629I23,
690G11, and 600B8) were purchased from Research Ge-
netics and regrown. Fifty-eight STS markers located in
the BCD regionwere used for clone veriﬁcation and contig
construction. Assembly of YACs, PACs, and BACs span-
ning the BCD region was accomplished by a combination
of PCR analysis of all clones for the presence or absence
of the STS markers and EcoRI and NotI restriction di-
gestion of YAC clones, followed by Southern blots of the
digested YAC clones probed with the PCR-ampliﬁed
products of the STS markers (Ayyagari et al. 1996).
Gene Structure and Sequence Analysis
Primer sequences that amplify each exon, including
the intron-exon boundaries, are available as table A1 of
appendix A (online only). cDNA structure was con-
ﬁrmed by direct PCR and 3′ and 5′ RACE from Mara-
thon-ready human retina cDNA (BD Biosciences) and
human RPE cDNA, shown in ﬁgure 2 with three sets of
primers for RT-PCR of transformed lymphoblastoid
lines and primary and nested primers for 3′ and 5′ RACE
(available as table A1 of appendix A [online only]). DNA
was sequenced with the ABI BigDye Terminator cycle
sequencing kit v3.1, according to the manufacturer’s rec-
ommendations (Applied Biosystems), through use of an
ABI 3100 sequencer. The sequence information was im-
ported into SeqMan 5.01 (DNASTAR), and sequences
of affected and normal individuals and consensus se-
quence were aligned to identify variations.
Expression Analysis
Expression of the novel gene CYP4V2 was tested by
PCR of cDNA from multiple human normal tissues with
primers for cDNA913, covering exons 5–11. Tissues in-
cluded human retina, RPE, lymphocytes, heart, brain,
placenta, lung, liver, skeletal muscle, kidney, and pan-
Figure 1 Pedigrees of selected families with BCD with haplotypes of markers in the BCD region. Family 33001 was used in the genomewide
scan. Recombinants in individual 4 of family 33010 and individual 6 of family 33011 set the centromeric boundary at D4S2924, as does the
lack of homozygosity in D4S3047, D4S3032, and D4S2924 in individual 3 of consanguineous family 33005.
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Figure 2 A, Physical map of BCD region at 4q35.1. The BCD region is covered contiguously by 6 overlapping YACs and 32 BACs,
representing the shortest path. The STS marker positions are from the NCBI database. B, CYP4V2 cDNAs. Five overlapping cDNA fragments
obtained by direct PCR and 5′ and 3′ RACE from human retinal cDNA and RPE cDNA provide a 2,041-bp cDNA. Sequence homology searches
show partial sequence overlap with three NCBI predicted cDNA sequences: XM209611, XM114391, andXM209612.C,CYP4V2 gene structure.
CYP4V2 gene structure is assembled by alignment of the cDNA sequence to genomic DNA sequence. The 11 identiﬁed exons are ﬂanked by
recognizable splice sites. The coding region extends as one ORF from the ﬁrst Met (ATG) codon in exon 1 to the stop (TAA) codon in exon
11. This novel gene consists of 11 exons and spans 19 kb. Thirteen mutations of the CYP4V2 gene found in 23 of 25 unrelated patients with
BCD are indicated below the gene structure.
creas from the Multiple Human Tissue cDNA Panels
(BD Biosciences). Expression status of CYP4V2 in pa-
tients with BCD was tested by RT-PCR with total RNA
isolated from patient lymphoblastoid lines andwas com-
pared with the expression in unaffected carriers and nor-
mal control individuals.
Molecular Modeling
Modeling of the CYP4V2 wild-type protein was per-
formed by homology modeling based on crystal coor-
dinates for mammalian CYP2C5 (Protein Data Bank
[PDB] ID 1dt6) and bacterial CYPBM3 (PDB ID 2hpd)
as the structural templates (Abola et al. 1987). Although
CYP2C5 oxidoreductase demonstrates an identity (sim-
ilarity) of 23% (43%), which is lower than that of
CYPBM3, 32% (51%), in regions containing the P450
domain, its homology covers a broader sequence range
(residues 18–448, shown in ﬁg. B1 of appendix B [online
only]). Thus, CYPBM3modeled the high-homology area
surrounding the active site, and CYP2C5 modeled the
amino terminal region, for which homology to CYPBM3
was low. Primary sequences were aligned by the method
of Needleman and Wunsch (1970) incorporated in the
program Look, version 3.5.2 (Lee and Subbiah 1991;
Lee 1994) for 3-D structure prediction. The location
of the transmembrane segment was predicted by the
TMHMM2 program incorporated in SMART (Schultz
et al. 1998). Finally, the monomeric CYP4V2 and exon
7 deleted mutant CYP4V2-exon7del were built by the
automatic segment matching method in the program
Look (Levitt 1992), followed by 500 cycles of energy
minimization. The same program generated the confor-
mation of the proteins with point mutations—W44R,
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Figure 3 Structure of CYP4V2 protein and selected mutations. A, CYP4V2 protein structure. a Helices are shown as red cylinders, b
sheets are shown as yellow ribbons, and the porphyrin ring is shown in blue. B, The peptide preserved by G134X, which truncates the protein
just within the main globular domain, is shown in red, and truncated sequences are shown in blue, with the exception of exon 7, which is
shown in green. C, The 15-bp deletion, including the 3′ (acceptor) splice site for exon 7, which removes the G, H, and part of the central I
helices (green) and their connecting loops and causes uncoiling and displacement of the central I helix (the normal position is shown in light
blue, and the displaced position is shown in dark blue). D, Replacement of hydrophobic aromatic tryptophan near or in the transmembrane
segment with positively charged arginine (W44R). E, R508H, which might inﬂuence heme coordination. F, H331P, predicted to disrupt the I
helix. G, I111T, near the surface of the molecule. H, S341P, predicted to disrupt the I helix.
G61S, I111T, S341P, and R508H—and reﬁned them by
self-consistent ensemble optimization (500 cycles) (Lee
1994). The predicted structure of CYP4V2 (ﬁg. 3) was
regularized by an energy minimization procedure in the
presence of water on the ﬁnal step through use of the
program Insight II version 2000.1 (Accelrys), and the
geometry of the predicted structures was tested with the
program Procheck (Laskowski et al. 1993).
Splice Site and Mutation Analysis
Computer analysis of the strength of splice sites of
genomic sequences spanning relevant nucleotides was
performed by the Delila package (Rogan et al. 1998;
Delila Program Web site). These programs use an in-
formation theory–based model of donor and acceptor
splice sites to assign a bit value as a representation of
the strength of interaction between the splice site and
the spliceosome for both the wild-type and the mutant
splice sites. Blosum scores (Henikoff andHenikoff 1992)
were taken from the Bioccelerator at the European
Molecular Biology Laboratory Web site. The blosum70
score was selected on the basis of the overall homology
levels among members of CYP450 protein families,
which tend to range from 60% to 80%.
Results
A physical map of the BCD region from D4S2924 to
4qter, with an approximate size of 4 Mb, shown in ﬁg.
2A, is consistent with the current versions of the Na-
tional Center for Biotechnology Information (NCBI
Home Page) and Celera (myScience Web site) databases.
As shown in table 1, two-point linkage analysis contin-
ues to suggest that the BCD gene is linked to markers
D4S2688 ( ; ), D4S426 ( ;Z p 4.14 vp 0 Z p 4.82max max
), and D4S2299 ( ; ). Obligatevp 0 Z p 5.43 vp 0max
recombinants are seen on two-point analysis for all
markers centromeric of D4S2924.
Haplotype analysis reﬁnes the critical interval further
(ﬁg. 1). Recombinants in families 33010 and 33011 set
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Table 1
Two-Point Linkage Results for Markers in the BCD Region of Chromosome 4q35
MARKER
POSITION (4PTEL) LOD SCORE AT v p
Zmax ˆvcM Mb 0 .01 .05 .1 .2 .3 .4
D4S3047 190.25 185.99  4.68 1.15 .06 .42 .29 .08 .42 .2
D4S3032 192.73 186.6  .45 1.30 1.36 .96 .52 .13 1.37 .06
D4S2924 193.15 187.03  1.5 .66 1.05 .91 .45 .10 1.09 .09
GDB186858 187.78 3.13 3.03 2.63 2.15 1.32 .64 .17 3.13 0
D4S3051 200.02 188.61 .09 1.35 1.68 1.47 1.01 .45 .15 1.7 .06
D4S3332 202.55 188.97 1.71 3.21 3.30 2.78 1.78 .88 .29 3.33 .03
D4S2921 202.69 189.48 1.19 2.54 2.82 2.55 1.68 .83 .26 2.82 .05
D4S2688 189.69 4.14 4.02 3.45 2.81 1.69 .79 .21 4.14 0
D4S426 202.69 189.69 4.82 4.58 4.04 3.30 2.03 1.00 .27 4.82 0
D4S2299 203.59 190.10 5.43 5.28 4.61 3.83 2.37 1.16 .39 5.43 0
D4S2390 204.18 190.34 2.57 4.04 4.01 3.45 2.15 1.02 .20 4.2 .03
D4S1652 204.46 190.67 1.05 2.46 2.59 2.24 1.37 .67 .14 2.69 .03
D4S2930 204.47 190.68 1.85 3.36 3.45 2.93 1.90 .88 .30 3.53 .02
D4S2283 190.9 2.04 3.33 3.36 2.88 1.76 .84 .18 3.52 .04
the centromeric boundary at D4S2924, as does a lack
of homozygosity in consanguineous family 33005. The
telomeric boundary of the linked interval is indeter-
minate but places BCD telomeric of D4S2924.
One predicted gene in this region, Hs4-22948-33-
121-2 in the NCBI database and HCG1787816 in the
Celera database, is highly homologous toMus musculus
protein cytochrome 4V3 of the cytochrome P450 su-
perfamily. PCR ampliﬁcation and direct sequencing
of the 11 putative exons and intron-exon boundaries
shows mutations in 13 of 14 familial and 10 of 11
isolated BCD cases (table 2). Mutations found in fa-
milial cases were conﬁrmed, in all available affected
family members, to cosegregate with BCD. RT-PCR am-
pliﬁcation and sequencing of lymphocyte mRNA from
patients with the 15-bp homozygous deletion, including
the exon 7 splice-acceptor site, conﬁrmed skipping of
exon 7 in these patients (ﬁg. 4). In familial cases, het-
erozygous mutations were conﬁrmed to reside on sep-
arate chromosomes by genotyping parents.
An isolated European patient, 3300013, is heterozy-
gous for an S341Pmutation and an IVS21GrAchange.
Information-theory analysis of the splice site with the
Delila program (Rogan et al. 1998; Delila Program Web
site) shows a decrease in the bit value of this 5′ (donor)
splice site from 8.6 to 5.6, consistent with a leaky mu-
tation. In addition, a 5.5-bit cryptic splice site 10 bases
downstream is likely to interfere with legitimate splicing
at themutant site. Transformed cell lines are not available
to conﬁrm this prediction. An isolated Japanese patient,
3300007, shows a heterozygous GrA transversion at
position 1 of the intron 2 5′ (donor) splice site, with
the only other change being IVS225delT. Fifty control
samples, including 12 of Chinese, 16 of Japanese, and
22 of European origin, were screened for thesemutations.
Only one heterozygous AC transversion in exon 8
(1296ArC in theCYP4V2mRNA, resulting in a putative
H331P) was found in a single Chinese control sample.
Assembly of sequences from overlapping 3′ and 5′
RACE products and PCR fragments extending from ex-
ons 1–4, 1–7, and 5–11, all obtained from ampliﬁcation
of Marathon-Ready human retina cDNA, provides a
2,041-bp cDNA sequence extending from the 5′ UTR
through the stop codon (TAA) and the 3′ UTR (ﬁg. 2).
It encodes a 525–amino acid protein for which BLASTP
shows 80% identity and 89% positives to Mus mus-
culus CYP4V3 (shown in ﬁg. B1 of appendix B [online
only]). The Motifs routine of the Wisconsin GCG pro-
gram (Devereux et al. 1984) and SMART (Schultz et
al. 1998) conﬁrm that this protein belongs to the P450
heme-thiolate protein superfamily. The Cytochrome
P450 Homepage lists CYP4V2 on chromosome 4q35.1,
and, since the predicted amino acid sequence shows
98% identity with the listed sequence, this nomencla-
ture is used. CYP4V2 is homologous to other members
of CYP450 family 4, suggesting that it might act on
fatty acids or steroids. We have previously shown ab-
normalities in n-3 polyunsaturated fatty acid metabo-
lism in patients with BCD (Lee et al. 2001).
The CYP4V2 structure based on homology modeling
is shown in ﬁgure 3, and homologous sequences are
shown in ﬁg. B1 of appendix B (online only). The pre-
dicted transmembrane segment resides near the amino
terminus, followed by a globular structural domain typ-
ical of the CYP450 family. The globular domain of
CYP4V2 comprises 18 helices and b structural segments
(ﬁg. 3A). The heme group, shown in blue, is located
close to the surface of the protein, coordinated by the
I helix towards the protein interior and the L helix
superﬁcially.
Possible effects of the BCD mutations based on the
atomic model described above are shown in table 2 and
Table 2





Score) Location in Protein Second Mutation (Ethnicity)a Predicted Effect
434TrA 1 W44R (3) Between transmembrane segment and A helix I111T in individual 3300010 (E) Increase the solubility of the transmembrane
helix C cap
485GrA 1 G61S (1) Between transmembrane segment and A helix Exon9del in family 33014 (C) Unknown
IVS21GrA (5′ [donor] splice site) 2 E72GNFNX Truncation between transmembrane segment
and A helix
?IVS225 delT in individual 3300007 (J) Eliminates entire globular structure of protein, no
enzymatic activity
IVS21GrA (5′ [donor] splice site) 2 E72GNF4NX Truncation between transmembrane segment
and A helix
S341P in individual 3300013 (E) Eliminates entire globular structure of protein, no
enzymatic activity
541GrT 2 E79D (1) Between A and B helices M123V in individual 3300005 (C) Unknown
636TrC 3 I111T (1) Between B and B’ helices (on protein surface) I111T in family 33010 (E), G134X in family
33011 (E), W44R in individual 3300010 (E)
Changes interaction with water
671ArG 3 M123V (1) B’ helix E79D in individual 3300005 (C) Unknown
704GrT 3 G134X Truncation between B’ and C helices I111T in family 33011 (E) Complete loss of the cytochrome P450 function
IVS68delTCATACAGGTCATC
(3′ [acceptor] splice site)
7 Exon7del In-frame deletion excising all of H and parts of
G and I helices
Exon7del in families 33002–33007 (J), 33008 (C),
33009 (C), and 33015 (C) and individuals
3300004 (C), 3300008 (C), and 3300009 (J);
exon9del in individual 3300012 (C); H331P in
family 33001 (C)
Decreased fatty acid binding, the cell attachment
site is removed, shorter long helix
1296ArC 8 H331P (2) I helix Exon7del in family 33001 (C) Change in conformation of central I helix; likely
disruption of heme iron coordination
1325TrC 8 S341P (1) I helix E72GNFNX in individual 3300013 (E) Change in conformation of the central I helix, as
in the IVS68delTCATACAGGTCATC
mutation
IVS82ArG (3′ [acceptor] splice
site)
9 Exon9del In-frame deletion excising 46 residues including
the K helix
G61S in family 33014 (C), exon7del in individual
3300012 (C), exon9del in individual 3300011
(C)
Removes ERR triad and destabilizes the meander
region
1827GrA 11 R508H (0) C terminus R508H in individual 3300001 (E) Change in fatty acid binding by reducing stability
of loop 495-516 and altering coordination of
heme iron
NOTE.—Mutations are listed in exon order with the second mutation in individual patients given in column 5, so that heterozygous affected individuals are listed twice. No mutations were found in two isolated
individuals of European descent (3301205 and 3300006).
a Ethnicity abbreviations are as follows: E p European, J p Japanese, C p Chinese. Because of its uncertain consequences, the IVS225delT sequence change is entered only as second mutation and is preceded
with a question mark (?).
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Figure 4 Expression pattern of CYP4V2. PCR was performed with cDNA from various tissues, using primers from exons 5 and 11. The
lymphocyte (“ptnt”) sample is from patient 4 in family 33002 and displays a 727-bp fragment lacking exon 7. The negative control is H2O,
and the positive control is pooled cDNA from human tissues (Universal cDNA pool [Clontech]).
ﬁgure 3. The most consequential are those in which large
parts of the molecule are absent. The intron 2 1GrA
5′ (donor) splice-site mutation is predicted by conceptual
translation to result in skipping of exon 2, resulting in a
frameshift in which the exon 1 sequence is followed by
a novel four–amino acid sequence (GNFN) prematurely
terminated before the conserved globular domain. A sec-
ond pathogenic mutation, G134X, would be expected to
truncate the peptide just within the globular domain (ﬁg.
3B), removing the amino acids that coordinate the heme
group and their supporting structures. A third pathogenic
mutation is the 15-bp deletion including the 3′ (acceptor)
splice site for exon 7, skipping exon 7. Exon 7 encodes
amino acids 268–329, which form the G, H, and part of
the central I helices and their connecting loops (ﬁg. 3A).
Their deletion not only eliminates these parts of the pro-
tein structure but also loosens and displaces the remain-
ing I helix and would displace many amino acids co-
coordinating the heme group, thus disrupting enzyme
activity (ﬁg. 3C). A fourth pathogenic mutation in the 3′
(acceptor) splice site, IVS82ArG, is predicted to cause
skipping of exon 9, resulting in excision from the protein
of the 46 amino acids encoded by exon 9, which include
the J’ and K helices. This is predicted to remove the two
residues of the ERR triad (E387 and R390 in the K helix),
destabilizing the critical meander region. This should re-
sult in loss of heme binding, with concomitant loss of
enzymatic activity.
Additional sequence changes, although not as dra-
matic as elimination of large parts of the protein se-
quence, seem highly likely to affect enzymatic activity
or localization of CYP4V2. Two of these are H331P
and S341P (ﬁg. 3F and 3H), each occurring in the cen-
tral I helix. Insertion of proline into this helix is pre-
dicted to inﬂuence the stability of the helical structure,
on which coordination of the heme group depends. A
third mutation, W44R (ﬁg. 3D), replaces a hydrophobic
aromatic tryptophan in or near the transmembrane seg-
ment with a positively charged arginine, which is likely
to disrupt insertion of CYP4V2 into the membrane, in-
terfering with protein localization. Finally, since R508
is predicted to coordinate the heme iron along with
R465, R508H, although a relatively conservative sub-
stitution with a blosum70 score of 0, might inﬂuence
heme coordination and substrate binding (ﬁg. 3E). Al-
though the remaining coding sequence changes result in
alterations of the amino acid sequence and are absent
from controls, their effects on CYP4V2 structure and
function are more difﬁcult to predict. Two, E79D and
M123V, have positive blosum70 scores (1), empha-
sizing their conservative nature, whereas two more,
G61S and I111T, have negative blosum70 scores (1).
Expression of CYP4V2 was observed by PCR of hu-
man tissue–speciﬁc cDNA from human heart, brain,
placenta, lung, liver, skeletal muscle, kidney, pancreas,
retina, RPE, and lymphocytes (ﬁg. 4), consistent with
earlier predictions of broad expression of this gene (Lee
et al. 2001). Although the heaviest bands are seen in
the retina, this analysis merely detects the presence of
the CYP4V2 mRNA and is not quantitative.
Discussion
We have reﬁned the position of the BCD locus to that
part of chromosome 4 distal to D4S2924 and describe
association of sequence changes in CYP4V2 with BCD.
Previous linkage analysis had placed the BCD locus on
chromosome 4q35 telomeric of D4S1652 (Jiao et al.
2000). Fine mapping with newly developed markers re-
stricted the BCD critical region to the region distal to
D4S2924. We have identiﬁed 13 putative mutations in
the CYP4V2 gene. Three of these mutations result in
termination of the peptide chain before the cytochrome
P450 structure is formed, and two more cause deletion
Li et al.: BCD Caused by CYP4V2 825
of large internal stretches of amino acids including parts
of the I helix, which might be critical for protein struc-
ture and positioning of the heme group. Although we
failed to detect mutations in two patients and detected
only a single certain mutation in one patient, it is possible
that some mutations were missed in the analysis, par-
ticularly those in promoter regions or in intronic regions
active in splicing, or large intragenic deletions present
in compound heterozygotes.
The CYP4V2 gene comprises 11 exons spanning 19
kb and is a novel member of the cytochrome P450 gene
family. The coding sequence begins in exon 1 and con-
tinues through exon 11. Although different sequences
corresponding to various parts of CYP4V2 are present
in the NCBI and Celera databases, analysis of mRNA in
the retina and RPE cells showed only the single sequence
shown in ﬁgure 4. Thus, although alternative splicing or
initiation may occur in a small fraction of transcripts in
these tissues, the major gene product is the one used in
this analysis. In addition, the protein predicted to result
from the mRNA structure aligns well with other cyto-
chrome P450 family members, and structural modeling
is consistent with a member of the cytochrome P450
family. Thus, it seems likely that this sequence is the
functional CYP4V2, although conﬁrmation awaits ex-
pression and biochemical characterization.
Comparison of theCYP4V2 sequencewith othermem-
bers of the cytochrome P450 gene family suggests that,
as is true for other members of the CYP4 family, it might
act in fatty acid metabolism. This would be consistent
with the results of Lee et al. (2001), which demonstrated
that BCD is characterized by a lower than normal con-
version of FA precursors into n-3PUFA. Both of these
ﬁndings raise the possibility that abnormal lipid metab-
olism associated with BCD is the result of defects in fatty
acid metabolism—possibly binding, elongation, or de-
saturation. The relationship between the absence of two
fatty acid–binding activities in lymphocytes frompatients
with BCD (Lee et al. 1998) and the genetic cause and
pathophysiology of the disease remains unexplained. The
genes encoding these proteins do not reside in the BCD
region on chromosome 4q35.1 (Jiao et al. 2000), sug-
gesting that they may be involved in subsequent steps of
the pathological process in this disease.
CYP4V2 is expressed in a wide variety of tissues,
consistent with inclusions and their clinical sequelae
occurring in the cornea, retina, and lymphocytes. Al-
though there is no reported functional impairment of
tissues other than the cornea and retina, it is unclear
whether careful histological characterization of addi-
tional tissues has been performed. Just as the inclusions
in lymphocytes do not appear to have any functional
consequences, inclusions might accumulate in other tis-
sues without causing clinically signiﬁcant abnormalities.
Here we report reﬁnement of the BCD region to chro-
mosome 4q35 distal to D4S2924 and association of
mutations in theCYP4V2 gene with BCD. The sequence
changes in the CYP4V2 gene are predicted to have func-
tional consequences on the basis of structural modeling
of the gene product and its mutant forms and their
absence from 100 control chromosomes. Although the
structure of CYP4V2 suggests that it may be active in
fatty acid metabolism, the speciﬁc enzymatic activity of
this cytochrome P450 family member remains to be elu-
cidated. Additional studies are under way to understand
the function of CYP450 and to identify the pathogenic
mechanisms underlying BCD.
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